This handout is for idiopathic pulmonary arterial hypertension (group 1 pah). Your care team identified this based on: progressive exertional dyspnea unexplained by left hd or lung disease (esc/ers 2022).
Other reasons your team may use this plan: exertional syncope / presyncope — high-risk pah presentation (esc/ers 2022); right hf signs — jvd, peripheral edema, ascites, hepatic congestion (esc/ers 2022); echo with rvsp >=40 mmhg, dilated rv, septal flattening, tapse <=17 mm (esc/ers 2022 humbert).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| macitentan | 10 mg | PO | once daily | SERAPHIN — reduced morbidity/mortality endpoint; once-daily; less hepatotoxic than bosentan |
| ambrisentan | 5 mg | PO | once daily | AMBITION dual upfront with tadalafil |
| tadalafil | 20 mg | PO | once daily | PHIRST + AMBITION; once-daily; no nitrate use |
| sildenafil | 20 mg | PO | TID | SUPER-1; less convenient than tadalafil; no nitrate use |
Plan: PAH-specific therapy by ESC/ERS 4-strata risk score
Use these zones to know what to do based on how you feel.
Call 911 or go to the nearest emergency room right away if you have:
PAH-specific exercise rehab; pneumococcal/influenza/COVID vaccinations; contraception counselling; mental-health support
Guideline: 2022 ESC/ERS Pulmonary Hypertension Guidelines + 2026 ATS/CHEST/PHA PAH Update